Discovery Life Sciences Builds New Site in Greater Boston Area


The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

Image Credit: Berkeley Investments

Image Credit: Berkeley Investments

Discovery Life Sciences, a provider of biospecimen solutions and laboratory services, is opening a new 53,000 square-foot office and laboratory site in Malden, MA.1 This specific facility marks the company’s seventh facility in the United States—its third in the Greater Boston area—alongside its Woburn and Quincy locations.

The Malden plant is intended to directly benefit the pharma and biotech industry. It will be home to Discovery's Gentest products and services, which feature in vitro preclinical studies for drug metabolism and predictive toxicology. There is also a clean room and cell processing laboratory to help boost its AllCells offerings, which provide cell and gene therapy (CGT) cryo-preserved good manufacturing practice (GMP) products on the East Coast.

"Our new Malden facility underscores our mission to enable the discovery and development of therapeutic solutions that improve patient outcomes," said Greg Herrem, Discovery CEO. "By expanding our footprint in the Greater Boston area in response to growing customer demand, we enhance our capacity to deliver same-day, cutting-edge cell and gene therapy solutions to biopharma customers based in the New England region."

Marshall Schreeder, president of Discovery's preclinical division, noted that the importance of building a facility in the Greater Boston area.

"The Greater Boston area is a global hub for biotech and pharmaceutical research, and our continued investment in this region demonstrates our dedication to being the most trusted partner in life sciences research and clinical development," he noted. "The new Malden facility will play a crucial role in supporting the continued growth of our Gentest business, offering enhanced capabilities for drug metabolism studies and predictive toxicology, which are essential for drug discovery and development."

Last October, Discovery moved to its new 93,000 square-foot global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, AL.2 Alongside the move, the company’s AllCells CGT brand also set up its new plant in Alameda, CA. Discovery even unveiled its Olink Explore HT proteomic services and is launching a digital platform.

The aforementioned Alameda plant features cell manufacturing and processing cleanrooms that meet EU standards; a 20% increase in collection capacity; and an upgraded donor experience with easy accessibility.

In order to meet its rising growth and client interest, Discovery even launched a new company website. The new features what the company describe as a “modernized design” and an “intuitive user interface” that can deliver a smoother and more streamlined digital experience.

“Following our acquisition of 13 companies over the last five years, we believe these enhancements mark a significant milestone in our company’s journey,” commented Glenn Bilawsky, the company’s former CEO. “We are reshaping the life sciences laboratory services sector. With these enhancements, we are even better equipped to advance science and accelerate our clients’ research and development of new diagnostics and therapies to improve patient care.”


1. Discovery Life Sciences Expands Presence with New Office and Lab in Greater Boston Area. PR Newswire. June 11, 2024. Accessed June 12, 2024.

2. Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements. Discovery Life Sciences. October 12, 2023. Accessed June 12, 2024.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.